Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia

Abstract

Introduction: Inotuzumab ozogamicin (CMC-544) is a humanized anti-CD22 monoclonal antibody conjugated with calicheamicin. Preclinical data indicate activity against B-cell tumors and early results from clinical trials indicate activity against B-cell lineage acute lymphoblastic leukemia (ALL).

Areas covered: This paper reviews the design, pharmacokinetic and pharmacodynamic characteristics, and preclinical and clinical experience of inotuzumab ozogamicin in adult ALL.

Expert opinion: Inotuzumab ozogamicin appears as an effective salvage therapy in patients with advanced ALL, allowing more patients to receive stem cell transplant (SCT) with encouraging response rates. This agent should provide a unique opportunity to treat selected ALL patient subpopulations.

Keywords::

• acute lymphoblastic leukemia
• CMC-544
• inotuzumab ozogamicin
• monoclonal antibody
• targeted therapy